Bioxytran (BIXT) Total Non-Current Liabilities (2022 - 2024)
Bioxytran (BIXT) posted Total Non-Current Liabilities of $1.7 million for Q4 2024, down 64.31% sequentially from $4.9 million in Q1 2022.
Bioxytran (BIXT) Total Non-Current Liabilities (2022 - 2024) Analysis & Trends
Bioxytran has reported Total Non-Current Liabilities for 2 years, with the latest figure at $1.7 million in Q4 2024.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $1.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.7 million (changed N/A YoY) and the FY2024 annual result came in at $1.7 million, changed N/A from the prior year.
- Total Non-Current Liabilities declined to $1.7 million in Q4 2024 per BIXT's latest filing, from $4.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $4.9 million in Q1 2022 and troughed at $1.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.74 Mn |
| Mar 31, 2022 | 4.89 Mn |